S. Stintzing , H. Müller-Huesmann , E. von der Heyde , I. Virchow , R. Greil , J. Kisro , P. Stübs , D. Buerkle , A. Distelrath , J. Wierecky , A. Wein , A. Gerger , D. Arnold , R.M. Fritsch , S. Hegewisch-Becker , A. Vogel , A.D. Wagner , T. Winder , D. Koeberle , G. Prager
{"title":"enorafenib联合西妥昔单抗治疗转移性、BRAF v600e突变的结直肠癌——欧洲多中心、多国、非介入性研究:BERING CRC的有效性和治疗现状","authors":"S. Stintzing , H. Müller-Huesmann , E. von der Heyde , I. Virchow , R. Greil , J. Kisro , P. Stübs , D. Buerkle , A. Distelrath , J. Wierecky , A. Wein , A. Gerger , D. Arnold , R.M. Fritsch , S. Hegewisch-Becker , A. Vogel , A.D. Wagner , T. Winder , D. Koeberle , G. Prager","doi":"10.1016/j.annonc.2025.05.052","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8000,"journal":{"name":"Annals of Oncology","volume":"36 ","pages":"Page S25"},"PeriodicalIF":65.4000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"40P Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma - Effectiveness and treatment reality of the European multi-centric, multi-national, non-interventional study: BERING CRC\",\"authors\":\"S. Stintzing , H. Müller-Huesmann , E. von der Heyde , I. Virchow , R. Greil , J. Kisro , P. Stübs , D. Buerkle , A. Distelrath , J. Wierecky , A. Wein , A. Gerger , D. Arnold , R.M. Fritsch , S. Hegewisch-Becker , A. Vogel , A.D. Wagner , T. Winder , D. Koeberle , G. Prager\",\"doi\":\"10.1016/j.annonc.2025.05.052\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8000,\"journal\":{\"name\":\"Annals of Oncology\",\"volume\":\"36 \",\"pages\":\"Page S25\"},\"PeriodicalIF\":65.4000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0923753425002558\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Oncology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0923753425002558","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
40P Encorafenib plus cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal carcinoma - Effectiveness and treatment reality of the European multi-centric, multi-national, non-interventional study: BERING CRC
期刊介绍:
Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine.
The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings.
Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.